Genetic variants and social benefit receipt in premenopausal women with breast cancer treated with docetaxel: a Danish population-based cohort study.
Breast cancer
Single-nucleotide polymorphisms
Social benefits
Survivorship
Taxane
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
20 Sep 2024
20 Sep 2024
Historique:
received:
09
07
2024
accepted:
25
08
2024
medline:
20
9
2024
pubmed:
20
9
2024
entrez:
20
9
2024
Statut:
aheadofprint
Résumé
Breast cancer patients' need for social benefits may increase following taxane-based chemotherapy, due to long-lasting side effects. Specific single nucleotide polymorphisms (SNPs) may mediate such side effects. We investigated the association between SNPs related to taxane metabolism, transport, toxicity, or DNA and neural repair, and receipt of social benefits. From the Danish Breast Cancer Group, we identified premenopausal women diagnosed with stage I-III breast cancer during 2007-2011 and treated with docetaxel-based chemotherapy. We genotyped 21 SNPs from archived breast tumors using TaqMan assays. We ascertained social benefit payments from 1 year before to 5 years after diagnosis, using nationwide, administrative registry data. For each week, we categorized women as receiving health-related benefits (including sick leave and disability pension), labor market-related benefits (including unemployment benefits), or as being self-supporting. We computed rate ratios (RRs) of social benefit receipt for variant carriers (heterozygotes plus homozygotes) vs. non-carriers, using negative binominal regression with robust variance estimation. Among 2430 women, 12% received health-related benefits before diagnosis, 80% at diagnosis, and ~ 24% 2 to 5 years after diagnosis. Labor market-related benefits were uncommon (3-6%). All RRs were near-null and/or imprecise. We found no clinically meaningful impact of the selected SNPs on social benefit receipt among premenopausal breast cancer survivors treated with docetaxel.
Identifiants
pubmed: 39302578
doi: 10.1007/s10549-024-07474-9
pii: 10.1007/s10549-024-07474-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Kræftens Bekæmpelse
ID : R359-A21368
Organisme : Kræftens Bekæmpelse
ID : R327-A19070
Organisme : Dansk Kræftforsknings Fond
ID : FID1839672
Organisme : US National Cancer Institute
ID : R01CA166825
Organisme : Novo Nordisk Fonden
ID : NNF19OC0058710
Organisme : Lundbeck Foundation
ID : R167-2013-15861
Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660
doi: 10.3322/caac.21660
pubmed: 33538338
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020) Global cancer observatory: cancer today. https://gco.iarc.fr/today . Accessed 14 Feb 2022
Baker J, Ajani J, Scotté F, Winther D, Martin M, Aapro MS, von Minckwitz G (2009) Docetaxel-related side effects and their management. Eur J Oncol Nurs 13:49–59. https://doi.org/10.1016/j.ejon.2008.10.003
doi: 10.1016/j.ejon.2008.10.003
pubmed: 19201649
Eckhoff L, Nielsen M, Moeller S, Knoop A (2011) TAXTOX—a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009. Acta Oncol 50:1075–1082. https://doi.org/10.3109/0284186x.2011.602111
doi: 10.3109/0284186x.2011.602111
pubmed: 21824038
Ewertz M, Qvortrup C, Eckhoff L (2015) Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol 54:587–591. https://doi.org/10.3109/0284186x.2014.995775
doi: 10.3109/0284186x.2014.995775
pubmed: 25751757
Plym A, Johansson ALV, Bower H, Wennstig AK, Fredriksson I, Ahlgren J, Lambe M (2020) Impact of chemotherapy, radiotherapy, and endocrine therapy on sick leave in women with early-stage breast cancer during a 5-year period: a population-based cohort study. Breast Cancer Res Treat 182:699–707. https://doi.org/10.1007/s10549-020-05720-4
doi: 10.1007/s10549-020-05720-4
pubmed: 32506337
pmcid: 7320921
Petersson LM, Vaez M, Nilsson MI, Saboonchi F, Alexanderson K, Olsson M, Wennman-Larsen A (2018) Sickness absence following breast cancer surgery: a two-year follow-up cohort study. Scand J Caring Sci 32:715–724. https://doi.org/10.1111/scs.12502
doi: 10.1111/scs.12502
pubmed: 29048131
Schmidt ME, Scherer S, Wiskemann J, Steindorf K (2019) Return to work after breast cancer: the role of treatment-related side effects and potential impact on quality of life. Eur J Cancer Care (Engl) 28:e13051. https://doi.org/10.1111/ecc.13051
doi: 10.1111/ecc.13051
pubmed: 31033073
van Egmond MP, Duijts SFA, Loyen A, Vermeulen SJ, van der Beek AJ, Anema JR (2017) Barriers and facilitators for return to work in cancer survivors with job loss experience: a focus group study. Eur J Cancer Care (Engl). https://doi.org/10.1111/ecc.12420
doi: 10.1111/ecc.12420
pubmed: 26603683
Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL (2012) A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 18:5099–5109. https://doi.org/10.1158/1078-0432.Ccr-12-1590
doi: 10.1158/1078-0432.Ccr-12-1590
pubmed: 22843789
pmcid: 3445665
Boora GK, Kulkarni AA, Kanwar R, Beyerlein P, Qin R, Banck MS, Ruddy KJ, Pleticha J, Lynch CA, Behrens RJ, Züchner S, Loprinzi CL, Beutler AS (2015) Association of the Charcot–Marie-tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (alliance). J Neurol Sci 357:35–40. https://doi.org/10.1016/j.jns.2015.06.056
doi: 10.1016/j.jns.2015.06.056
pubmed: 26143528
pmcid: 4575633
Eckhoff L, Feddersen S, Knoop AS, Ewertz M, Bergmann TK (2015) Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer. Acta Oncol 54:530–537. https://doi.org/10.3109/0284186x.2014.969846
doi: 10.3109/0284186x.2014.969846
pubmed: 25383449
Kus T, Aktas G, Kalender ME, Demiryurek AT, Ulasli M, Oztuzcu S, Sevinc A, Kul S, Camci C (2016) Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. Onco Targets Ther 9:5073–5080. https://doi.org/10.2147/ott.S106574
doi: 10.2147/ott.S106574
pubmed: 27574448
pmcid: 4990373
Ahern TP, Collin LJ, Baurley JW, Kjærsgaard A, Nash R, Maliniak ML, Damkier P, Zwick ME, Isett RB, Christiansen PM, Ejlertsen B, Lauridsen KL, Christensen KB, Silliman RA, Sørensen HT, Tramm T, Hamilton-Dutoit S, Lash TL, Cronin-Fenton D (2020) Metabolic pathway analysis and effectiveness of tamoxifen in danish breast cancer patients. Cancer Epidemiol Biomarkers Prev 29:582–590. https://doi.org/10.1158/1055-9965.Epi-19-0833
doi: 10.1158/1055-9965.Epi-19-0833
pubmed: 31932415
pmcid: 7060091
Hjorth CF, Damkier P, Stage TB, Feddersen S, Hamilton-Dutoit S, Ejlertsen B, Lash TL, Bøggild H, Sørensen HT, Cronin-Fenton D (2023) The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer. Cancer Chemother Pharmacol 91:157–165. https://doi.org/10.1007/s00280-022-04499-z
doi: 10.1007/s00280-022-04499-z
pubmed: 36598552
pmcid: 9905159
Schmidt M, Schmidt SAJ, Adelborg K, Sundbøll J, Laugesen K, Ehrenstein V, Sørensen HT (2019) The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol 11:563–591. https://doi.org/10.2147/clep.S179083
doi: 10.2147/clep.S179083
pubmed: 31372058
pmcid: 6634267
Christiansen P, Ejlertsen B, Jensen MB, Mouridsen H (2016) Danish breast cancer cooperative group. Clin Epidemiol 8:445–449. https://doi.org/10.2147/clep.S99457
doi: 10.2147/clep.S99457
pubmed: 27822082
pmcid: 5094574
Blichert-Toft M, Christiansen P, Mouridsen HT (2008) Danish breast cancer cooperative group–DBCG: history, organization, and status of scientific achievements at 30-year anniversary. Acta Oncol 47:497–505. https://doi.org/10.1080/02841860802068615
doi: 10.1080/02841860802068615
pubmed: 18465316
Erichsen R, Lash TL, Hamilton-Dutoit SJ, Bjerregaard B, Vyberg M, Pedersen L (2010) Existing data sources for clinical epidemiology: the Danish national pathology registry and data bank. Clin Epidemiol 2:51–56. https://doi.org/10.2147/clep.s9908
doi: 10.2147/clep.s9908
pubmed: 20865103
pmcid: 2943174
Hjollund NH, Larsen FB, Andersen JH (2007) Register-based follow-up of social benefits and other transfer payments: accuracy and degree of completeness in a Danish interdepartmental administrative database compared with a population-based survey. Scand J Public Health 35:497–502. https://doi.org/10.1080/14034940701271882
doi: 10.1080/14034940701271882
pubmed: 17852980
Stapelfeldt CM, Jensen C, Andersen NT, Fleten N, Nielsen CV (2012) Validation of sick leave measures: self-reported sick leave and sickness benefit data from a Danish national register compared to multiple workplace-registered sick leave spells in a Danish municipality. BMC Public Health 12:661. https://doi.org/10.1186/1471-2458-12-661
doi: 10.1186/1471-2458-12-661
pubmed: 22894644
pmcid: 3511193
Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT (2015) The Danish national patient registry: a review of content, data quality, and research potential. Clin Epidemiol 7:449–490. https://doi.org/10.2147/clep.S91125
doi: 10.2147/clep.S91125
pubmed: 26604824
pmcid: 4655913
Statistics Denmark (2023) Husstande og familier [Housholds and families]. https://www.dst.dk/da/Statistik/emner/borgere/husstande-familier-og-boern/husstande-og-familier . Accessed 20 Mar 2023
Jensen VM, Rasmussen AW (2011) Danish education registers. Scand J Public Health 39:91–94. https://doi.org/10.1177/1403494810394715
doi: 10.1177/1403494810394715
pubmed: 21775362
Collin LJ, Cronin-Fenton DP, Ahern TP, Christiansen PM, Damkier P, Ejlertsen B, Hamilton-Dutoit S, Kjærsgaard A, Silliman RA, Sørensen HT, Lash TL (2018) Cohort profile: the predictors of breast cancer recurrence (ProBe CaRE) premenopausal breast cancer cohort study in Denmark. BMJ Open 8:e021805. https://doi.org/10.1136/bmjopen-2018-021805
doi: 10.1136/bmjopen-2018-021805
pubmed: 30068618
pmcid: 6074634
Cronin-Fenton DP, Kjærsgaard A, Ahern TP, Mele M, Ewertz M, Hamilton-Dutoit S, Christiansen PM, Ejlertsen B, Sørensen HT, Lash TL, Silliman RA (2017) Validity of Danish breast cancer group (DBCG) registry data used in the predictors of breast cancer recurrence (ProBeCaRe) premenopausal breast cancer cohort study. Acta Oncol 56:1155–1160. https://doi.org/10.1080/0284186x.2017.1327720
doi: 10.1080/0284186x.2017.1327720
pubmed: 28585885
Møller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, Christiansen P, Mouridsen HT (2008) The clinical database and the treatment guidelines of the Danish breast cancer cooperative group (DBCG); its 30-years experience and future promise. Acta Oncol 47:506–524. https://doi.org/10.1080/02841860802059259
doi: 10.1080/02841860802059259
pubmed: 18465317
Ejlertsen B, Tuxen MK, Jakobsen EH, Jensen MB, Knoop AS, Højris I, Ewertz M, Balslev E, Danø H, Vestlev PM, Kenholm J, Nielsen DL, Bechmann T, Andersson M, Cold S, Nielsen HM, Maae E, Carlsen D, Mouridsen HT (2017) Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TOP2A-normal breast cancer: DBCG 07-READ, an open-label, phase III, randomized trial. J Clin Oncol 35:2639–2646. https://doi.org/10.1200/jco.2017.72.3494
doi: 10.1200/jco.2017.72.3494
pubmed: 28661759
Hjorth CF, Damkier P, Stage TB, Feddersen S, Hamilton-Dutoit S, Rørth M, Ejlertsen B, Lash TL, Ahern TP, Sørensen HT, Cronin-Fenton D (2022) Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark. Breast Cancer Res Treat 194:353–363. https://doi.org/10.1007/s10549-022-06596-2
doi: 10.1007/s10549-022-06596-2
pubmed: 35501422
pmcid: 9239972
Hjorth CF, Schmidt JA, Farkas DK, Cronin-Fenton D (2024) Social characteristics and social benefit use among premenopausal breast cancer survivors in Denmark: a population-based cohort study. J Cancer Surviv. https://doi.org/10.1007/s11764-024-01598-z
doi: 10.1007/s11764-024-01598-z
pubmed: 38647591
DA Analysis (2019) Store omkostninger ved sygefravær gør det svært for virksomhederne at integrere folk på kanten af arbejdsmarkedet [Extensive costs of sick leave make it difficult for companies to integrate people on the edge of the labour market]. https://www.da.dk/politik-og-analyser/beskaeftigelse/2019/store-omkostninger-ved-sygefravaer-goer-det-svaert-for-virksomhederne-at-integrere-folk-paa-kanten-af-arbejdsmarkedet/ . Accessed 6 Mar 2024
Jensen V, Lundager B, Christensen AL, Fonager K (2014) Unemployment under the flex job scheme increases the risk of permanent social security benefits. Dan Med J 61:A4804
pubmed: 24814586
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383. https://doi.org/10.1016/0021-9681(87)90171-8
doi: 10.1016/0021-9681(87)90171-8
pubmed: 3558716
Kvillemo P, Mittendorfer-Rutz E, Bränström R, Nilsson K, Alexanderson K (2017) Sickness absence and disability pension after breast cancer diagnosis: a 5-Year nationwide cohort study. J Clin Oncol 35:2044–2052. https://doi.org/10.1200/jco.2015.66.0613
doi: 10.1200/jco.2015.66.0613
pubmed: 28459607
Staff NP, Fehrenbacher JC, Caillaud M, Damaj MI, Segal RA, Rieger S (2020) Pathogenesis of paclitaxel-induced peripheral neuropathy: a current review of in vitro and in vivo findings using rodent and human model systems. Exp Neurol 324:113121. https://doi.org/10.1016/j.expneurol.2019.113121
doi: 10.1016/j.expneurol.2019.113121
pubmed: 31758983
Argyriou AA, Bruna J, Genazzani AA, Cavaletti G (2017) Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics. Nat Rev Neurol 13:492–504. https://doi.org/10.1038/nrneurol.2017.88
doi: 10.1038/nrneurol.2017.88
pubmed: 28664909
Lash TL, Cole SR (2009) Immortal person-time in studies of cancer outcomes. J Clin Oncol 27:e55–e56. https://doi.org/10.1200/jco.2009.24.1877
doi: 10.1200/jco.2009.24.1877
pubmed: 19597013
Ahern TP, Christensen M, Cronin-Fenton DP, Lunetta KL, Rosenberg CL, Sørensen HT, Lash TL, Hamilton-Dutoit S (2010) Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue. Clin Epidemiol 2:241–246. https://doi.org/10.2147/clep.S13811
doi: 10.2147/clep.S13811
pubmed: 21152250
pmcid: 2998813
Hertz DL, Kidwell KM, Thibert JN, Gersch C, Regan MM, Skaar TC, Henry NL, Hayes DF, Van Poznak CH, Rae JM (2015) Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses. Mol Oncol 9:1868–1876. https://doi.org/10.1016/j.molonc.2015.07.002
doi: 10.1016/j.molonc.2015.07.002
pubmed: 26276228
pmcid: 4624024